



KHIRON
L I F E S C I E N C E S C O R P

**A GLOBAL CANNABIS COMPANY IMPROVING THE
QUALITY OF PEOPLE'S LIVES**

TSXV: KHRN | OTCQX: KHRNF | FRANKFURT: A2JMZC

May 2020

Legal Notices



This information in this presentation is current as of April 1, 2020 unless otherwise indicated. The information contained in this presentation is provided for informational purposes only and does not constitute an offer to issue or arrange to issue, or the solicitation of an offer to issue, securities of Khiron. No part of this presentation shall form the basis or be relied upon in connection with any contract, commitment or investment decisions in relation thereto. The information contained herein is not investment advice and is not intended to be used as the basis for making an investment decision. No securities commission or similar regulatory authority in Canada has reviewed this presentation. Investors and prospective investors should rely only on the information contained in the continuous disclosure filings of Khiron on www.SEDAR.com under Khiron's issuer profile. This presentation is qualified in its entirety by reference to, and must be read in conjunction with, such filings.


This presentation contains "forward-looking statements," within the meaning of applicable Canadian securities laws. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations, assumptions and analyses made by us regarding the future of our business, future plans and strategies, our operational results and other future conditions. These forward-looking statements appear in a number of places throughout this presentation and can be identified by the use of words, such as "anticipates," or "believes," "budget," "estimates," "expects," or "is expected," "forecasts," "intends," "plans," "scheduled," or variations of such words and phrases or state that certain actions, events or results "may," "might," "will," "would," "could," "should," "continue," or be taken, occur or be achieved. These forward-looking statements relate to, among other things, our future financial performance, financial condition, liquidity, levels of activity, performance, prospects, growth, goals or achievements or other future events. Although we base the forward-looking statements contained in this presentation on assumptions that we believe are reasonable, these forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual performance and financial results in future periods to differ materially from those anticipated in our forward-looking statements, including those risk factors identified in Khiron's most recent MD&A, AIF and other disclosure documents available on SEDAR at www.SEDAR.com under Khiron's issuer profile. Forward-looking statements do not take into account the effect that transactions or non-recurring or other special items announced or occurring after the statements are made have on our business. For example, they do not include the effect of asset impairments or other charges announced or occurring after the forward-looking statements are made. The financial impact of such transactions and non-recurring and other special items can be complex and necessarily depends on the facts particular to each of them. Despite a careful process to prepare and review the forward-looking statements, there can be no assurance that the underlying opinions, estimates, and assumptions will prove to be correct. The purpose of the forward-looking statements is to provide the reader with a description of management's expectations regarding our anticipated future performance and may not be appropriate for other purposes. Furthermore, unless otherwise stated, the forward-looking statements contained in this report are made as of the date of this report and we do not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise unless required by applicable legislation or regulation. The forward-looking statements contained in this document are expressly qualified by this cautionary statement.

Market Research and Public Data: This corporate presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although we believe these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. We have not independently verified any of the data from third party sources referred to in this presentation and accordingly, the accuracy and completeness of such data is not guaranteed.

Future Oriented Financial Information: To the extent any forward-looking information in this corporate presentation constitutes "future-oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out above. Our actual financial position and results of operations may differ materially from management's current expectations and, as a result, our revenue and profitability may differ materially from the revenue and profitability profiles provided in this corporate presentation. Such information is presented for illustrative purposes only and may not be an indication of our actual financial position or results of operations.

Use of Non-GAAP Measures: This document refers to certain financial performance measures that are not defined by and do not have any standardized meaning under GAAP and are used by management to assess the financial and operational performance of the Company, including EBITDA, because certain investors may use this information to assess our performance and also determine our ability to generate cash flow. This data is furnished to provide additional information and are non-GAAP measures and do not have any standardized meaning prescribed by GAAP. They should not be considered in isolation as a substitute for measures of performance prepared in accordance with GAAP and is not necessarily indicative of operating costs presented under GAAP.

Current and Near Term Geographies



Leading Vertically Integrated Global Medical and CPG Cannabis Company



- ✓ **Vertically integrated** global cannabis company.
- ✓ High-quality **cannabis-derived medical and wellbeing products** for sale in Latam and around the world ⁽¹⁾
- ✓ Established **infrastructure** to address unmet medical cannabis needs around the world
- ✓ Leveraged **1st mover advantage** to become a leader in Latam ⁽²⁾
- ✓ Spent past **3 years** focusing on educating patients and physicians on the benefits of medical cannabis
- ✓ Only company authorized to **sell medical cannabis** in Colombia and **export** high-THC cannabis from Colombia



(1) Received quota to sell 9.3 tonnes of high-THC cannabis in Colombia (17% of total Colombian allocation)

(2) (e.g. 1st to sell CBD cosmetics in Colombia, 1st to receive high-THC quota)

KHIRON MED

Medical Cannabis

- THC and CBD medical cannabis products ⁽¹⁾

Project Twenty21

- Khiron supply Europe's largest medical cannabis study with 20,000 patients

KHIRON HEALTH SERVICES

Medical Clinics

- Owns & operates 3 medical clinics in Colombia
- Include medical cannabis as a therapeutic alternative.
- Currently services over 120,000 patients per year

KHIRON WELLBEING

Kuida

- 1st CBD-based portfolio of skin care products in Colombia
- Available in Colombia through 300 retail stores and e-commerce channels in US & UK



(1) Sales begin in Colombia Q1 2020 & Expected to begin in Brazil, Peru and the E.U throughout 2020

Strategic Focus on Patients & Doctors

Health Partnerships

3

Scientific Research Agreements Across the World

2

Medical Education Agreements with Top Universities in Latam

Health Care Providers / Medical Education Programs

Improve relationships with health care providers through medical congresses, e-learning and medical reps/MSL

Doctors create a pathway for referrals to Khiron via prescription or through clinic referrals

Sales Distribution – Clinics & Pharmacies

Own & Operate 3 clinics ⁽²⁾



Unique approach to customer acquisitions by focusing on relationships and education



Project Twenty21


Khiron as 1 of 7 companies & only Latin American company.

Project Overview

- Europe's 1st & largest national medical cannabis registry
- Treatments provided at clinics in the U.K. or through doctor prescription
- Create evidence for the effectiveness and tolerability of medical cannabis in UK



Timeline



Conditions



Khiron Supply Involvement

- Increase patient base over time
- Cost effective patient acquisition
- 1st access to potential market of 1.4+ million people who are currently self-medicating



Full Production to Meet Demand

Infrastructure for Medical Cannabis Production



- Fully licensed for THC and CBD cultivation in Colombia
- Dried flower cultivation capacity of **8,000 kg / year**

CULTIVATION



- **14,000 sq. ft. GMP compliant** extraction & ISO 17025 compliant testing lab.
- Dry Flower Extraction capacity of **80 tonnes / year**

EXTRACTION / PROCESSING



- Formulations include high THC, balance 1:1, low THC and pure CBD (1) (2)

PRODUCT FORMULATION



- **GEP-certified** 3rd party bottling and labeling lab in Colombia - Exclusive to Khiron for cannabis products

PRODUCT MANUFACTURING



(1) Products are based on a portfolio of 20+ THC and CBD strains already registered with the ICA (Instituto Colombiano Agropecuario (Colombian Agricultural Institute)

(2) Good Elaboration Practice

Direct Patients Access

KHIRON HEALTH SERVICES



Offers a comprehensive suite of health and medical services in alignment with insurance companies




Clinics serve as pharmacy centers for dispensing medical cannabis products



Patient data gathered and used to develop new and improved formulations

Khiron Clinic Transactions ⁽¹⁾



*As for December 2019

1) Medical transactions include: consultation, surgical procedure, therapeutic support, diagnostic service, etc.

Unique Medical Clinic Model

Integrative Medical Care Service strategy to treat “Body, Mind and Spirit” with medical cannabis and other complementary services

- **Main Units:** Pain unit, mental unit, neurology unit, odontology and surgery
- **Support services:** Integrative medicine, diagnostics support, hydrotherapy, acupuncture and rehabilitation

1

Clinic

15,000
Sq. Ft

Foot Print

100,000

Patients
Capacity



Unique Medical Clinic Model: Neurological Clinics

- ✓ Neurological
- ✓ Psychiatric
- ✓ Respiratory
- ✓ Urological
- ✓ Sleep and Orthopedic Diseases



Clinics in
Bogotá



Foot Print



Patients
Capacity

Continued Expansion of the Remote Platform

COVID-19 Response⁽¹⁾


Khiron Meets Essential Patient Needs with Teleconsultation Services in Colombia

✓ Gives **patients access** to clinic services and doctors trained to prescribe medical cannabis.

✓ Highly complementary to current **medical insured service offerings**.

✓ **Teleconsultation service** anticipated to quickly expand to meet potential growing demand for telehealth services.

✓ Virtual medical services complement Khiron's delivery service that is already successfully **delivering prescriptions directly to patients' homes**



Online Medical Cannabis Education Program


✓ Agreement with top-3 Latam university, located in Mexico.



✓ Bring online **medical cannabis education program** to an initial group of up to **1,500 physicians / healthcare practitioners** in Latam.

✓ Allows Khiron to include its medical education program with Tec de Monterrey's world-renowned **continuing education platform**

✓ Courses will begin in **Q2 2020**



- 13 modules (Basic and Advanced)
- Online courses taught by experts in Medical Cannabis



1) Khiron and its clinics continue to be operational during the COVID-19 pandemic under an exemption decreed by the Government of Colombia (i.e. essential service)

Focused on Consumers and Distribution

KHIRON
K U I D A
— CANNABIS COSMECEUTICS

A unique formulation which provides better water retention, elasticity, firmness and protection against free radicals




Hemp-derived CBD for your skin!

— WE DO IT DIFFERENT —



Kuida is Khiron's consumer brand of cannabis-based products for beauty, lifestyle, fitness, nutrition and healthy living





Creation of various consumer touchpoints
in store / online

First-to-market strategy has provided a large retail partner network which are currently selling Khiron products

~350 POS and pop-up stores in prominent malls



Kuida Own E-Commerce platform



Global Operations

A Global Team



250+ employees
20% insider & management owned*

*Fully Diluted as for Nov 25, 2019

Experienced Management Team



Alvaro Torres, CEO & Board Director

- Industrial Engineer who built infrastructure projects in Colombia and LatAm.
- Formerly with SNC Lavalin and successfully built an engineering and merchant banking firm.



Chris Naprawa, President

- 20+ years of experience in institutional capital markets.
- Former partner at Sprott Capital Partners, Head of Equity Sales at Macquarie Canada, Head of Equity Sales and Trading at Dundee Securities and Managing Director at Primary Capital.



Matt Murphy, VP Compliance

- 25 years with the U.S. DEA. Served in variety of positions, including Chief of Pharmaceutical Investigations, prior to founding the Pharma Compliance Group.



Tejinder Virk, President Khiron Europe

- 15 years of executive-level experience in the capital markets and cannabis industry.
- Previously served as a Managing Director in Europe, for Canopy Growth Corp. Formerly Managing Director of Global Equity Products for BMO Capital Markets.



Elsa Navarro, Wellbeing VP

- 10 years of experience in marketing and sales strategies in multiple industries such as dermo cosmetics, agro, bio-fuel, event and food & beverages companies.



Wendy Kaufman, CFO, CPA

- +20 years of international financial experience, within Latin American and European operations.
- Experienced positions as CFO at Pasinex Resources Limited, Primero Mining Corporation, and Vice President, Finance and Treasury at Inmet Mining Corporation.



Juan Diego Alvarez, VP Regulatory

- 10+ years of legal experience.
- Authority in Colombian medical cannabis regulation. Appointed by Minister of Health to create and draft regulations for legalization of medical cannabis.



Andres Galofre, VP Business Development

- 15+ years of leadership experience in pharmaceutical marketing, brand management, and distribution of ethical drugs and consumer products in Latin America.
- Led Advil launch in Colombia that reached 30% of domestic market share from inception.



Martha Oyuela, Health VP

- Former Director Marketing Manager in Bayer SA and Institutional Development Director for the Instituto Roosevelt
- 20+ years of experience in the managing and positioning services in health care institutions



Rodrigo Duran, Pharma VP

- 17 years of experience in CPG & Pharma marketing, sales and go-to-market strategies, managing teams, and bringing brands across the Latam markets.
- Former manager executive of Team Food, Pfizer and Wyeth.

Experienced Independent Board of Directors

Global Branding, Project and Regional Business Expertise



Alvaro Torres
Interim Chairman

- Industrial Engineer who built infrastructure projects in Colombia and LatAm.
- Formerly with SNC Lavalin and successfully built an engineering and merchant banking firm.



Vicente Fox
Independent Director

- Mexican businessman and politician who served as 55th President of Mexico.
- Former CEO Coca-Cola Mexico.



Deborah Rosati
Independent Director

- Over 30 years of experience, including in consumer, cannabis, private equity and venture capital.
- Vice Chair & Chair of the Audit Committee at cannabis authority Lift & Co (TSXV: LIFT).
- Former Chair of the Audit Committee at Sears Canada Inc., member of the Department Audit Committee at Correction Services Canada, and former Board member and Chair of the Audit Committee. at NexJ Systems Inc. .



Alvaro Yañez
Independent Director

- 15 years of legal experience in Colombia and internationally.
- Former Legal Manager of Frontera Energy (formerly known as "Pacific Exploration and Production").



Michael Beck
Independent Director

- Founder / Managing Director of Regent Advisors LLC.
- Former Managing Director of Rothschild.

Capital Structure & Coverage



Basic Shares Outstanding ¹	116 million
Recent Share Price (CAD) ²	\$0.7
Current Market Capitalization (CAD) ¹	\$80 million
Aligned Management and Board ³	20%
Warrants, Options and RSU`s Outstanding	14.3 million
Weighted Average Strike Price for Warrants (CAD)	\$1.83
Cash (CAD) ¹	\$36.4 million

ANALYST COVERAGE

FIRM	ANALYST
Canaccord Genuity	Kim Hedlin
AltaCorp Capital Inc.	David M. Kideckel
Bryan, Garnier & Co.	Nikolaas Faaes

Note:

1) As at March 31, 2020

2) As at May 1, 2020

3) Fully Diluted as for Nov 25, 2019

INVESTMENT HIGHLIGHTS



1

Leader in the Latin American medical cannabis market

2

Established portfolio of clinics with recurring customers and revenue

3

Medical cannabis and consumer product focused

4

Strong balance sheet and margin profile with clear path to profitability

5

**Strong management team and Board of Directors
20% Insider & Management Ownership***



Alvaro Torres
CEO

Bogotá, Colombia
Tel: +57 (320) 4950326
Email: aftorres@khiron.ca

Chris Naprawa
President

Toronto, ON, Canada
Tel: +1 (416) 705-1144
Email: cnaprawa@khiron.ca
investors@khiron.ca

Tejinder Virk
E.U President

London, UK
Tel: +44 (0) 79127-41995
Email: tvirk@khiron.ca

*Visit Khiron online at investors.khiron.ca
and on Instagram @khironlife*

